The market for clinical pharmacist services to Primary Care Networks has grown significantly since ARRS was introduced, and the choice of provider now matters more than it did in the early years of the scheme. Different providers deliver against the same ARRS budget in different ways, and the practical experience of working with them varies more than the pricing model alone suggests. Reviewing the best clinical pharmacist providers available to a network is best treated as a service-design decision, not a procurement exercise.
The features that separate high-performing providers from average ones are consistent across networks. Clarity of scope, quality of supervision, appropriate deployment model, prescribing status of the pharmacists supplied and demonstrated outcomes on SMR delivery all shape whether the pharmacist capacity a network buys translates into the measurable benefits ARRS was designed to enable.
Key takeaways
- The provider decision is more consequential in 2026/27 than earlier ARRS years, as networks now trade off pharmacist capacity against other ARRS roles from a single budget.
- Governance and named clinical supervision arrangements are the strongest indicator of provider quality that a network can assess up front.
- Deployment model flexibility (embedded, PCN-wide, remote or hybrid) should match the network’s clinical priorities rather than the provider’s default offering.
- Prescribing status matters: around two-thirds of pharmacists delivering SMRs now hold independent prescribing qualifications, and networks that recruit non-prescribers should factor in the additional GP time required for prescription signing.
- Published evidence links properly deployed clinical pharmacist services to measurable reductions in medicines spend, opioid prescribing and anxiolytic use.
How the provider decision has changed for 2026/27
The merger of the ARRS pots and the removal of role caps under the 2025/26 restructuring means that networks now decide how much of their ARRS budget to allocate to pharmacist capacity in competition with every other covered role. A provider that delivers marginal clinical value at contract level is now displacing capacity that could have gone to other clinical priorities.
The pending transition to local provider contracts from around 2027/28 also matters. Networks that commit to providers whose service model would translate cleanly to the successor framework preserve more operational continuity than those tied to arrangements built around the current DES structure alone.
Governance and clinical supervision arrangements
Governance is the single most useful indicator of provider quality that a network can assess before signing a contract. What to look for:
- A named clinical supervisor for every pharmacist provided, with the supervision hours agreed in the contract.
- Documented scope of practice for each role, with agreed escalation routes for cases outside pharmacist scope.
- Regular audit of prescribing decisions and SMR quality against a defined standard.
- Clear protocols for MHRA drug safety alert response across the practices the pharmacist covers.
Providers who can produce these documents on request tend to run services with fewer surprises. Providers who describe them in general terms without documentation should raise a flag.
Deployment model flexibility
Matching the model to the network’s clinical priorities
The four common deployment models (practice-embedded, PCN-wide, remote and hybrid) each match different network profiles. A network with significant care home populations needs a provider comfortable with regular on-site rounds. A network with recruitment gaps across widely dispersed practices benefits from a remote or hybrid model. Providers who only offer one deployment model force the network to adapt rather than the other way round.
Service continuity when a pharmacist moves on
Pharmacist turnover is a recurring risk in any long-term service arrangement. Well-run providers document handover explicitly and can supply cover during recruitment gaps rather than leaving practices without pharmacist input for weeks. Ask about the provider’s approach to continuity before signing, not after the first pharmacist leaves.
Prescribing status and scope
The BMJ Open 2025 national survey of pharmacists delivering SMRs found that around two-thirds now hold independent prescribing qualifications, a share that gives networks a useful benchmark for what to expect from a provider today. A provider whose pharmacists are predominantly non-prescribers is not necessarily wrong for every network, but the operational implication is real: every prescription that follows a pharmacist consultation needs a GP signature, which adds workflow steps and consumes GP time the pharmacist was supposed to release.
The Royal Pharmaceutical Society prescribing competency framework is the reference point networks should use when reviewing what a prescribing pharmacist is expected to demonstrate.
Track record with SMR delivery and outcomes
The BJGP February 2025 cohort study compared practices employing clinical pharmacists with those that did not, and identified measurable outcomes in medicines cost, opioid prescribing and anxiolytic use. Providers who can point to comparable outcomes across the networks they serve are demonstrating something the sector as a whole is now expected to deliver. Networks reviewing shortlists should ask providers for their outcomes data, not just their staffing numbers.
Reviewing shortlists and finalising the choice
Once governance, model flexibility, prescribing status and outcomes are on the table, the decision becomes a fit assessment rather than a procurement scoring exercise. Networks that describe their clinical priorities clearly, then ask providers how they would deliver against them, tend to end up with better fits than those that ask providers to describe what they offer in the abstract.
The choice of clinical pharmacist provider made well pays back across the whole ARRS spend, not just the pharmacist contract itself. Selecting a provider whose service structure matches the network’s clinical priorities and 2026/27 delivery expectations sets up the pharmacist workforce to deliver measurable outcomes, rather than leaving the value of the ARRS spend to depend on the individual pharmacist in post.
